The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Guest Editorial

A “new normal” for NCI-sponsored clinical trials is long overdue

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

I read with interest the recently published story on the recommendations to streamline data collection in certain NCI trials presented at the Nov. 9, 2022, meeting of the Clinical and Translational Research Committee (The Cancer Letter, Nov. 11, 2022).

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Richard L. Schilsky, MD, FACP, FSCT, FASCO
Professor emeritus, University of Chicago; Former chief medical officer and executive vice president, American Society of Clinical Oncology; Former chair, Cancer and Leukemia Group B
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Trodelvy reduces risk of disease progression or death by 38% vs. chemo as first-line therapy in metastatic TNBC

Data from the phase III ASCENT-03 study demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival for Trodelvy (sacituzumab govitecan-hziy) compared to chemotherapy as first-line treatment in patients with metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitors. 
Clinical Roundup

Keytruda + Padcev reduced risk of EFS events and death for muscle-invasive bladder cancer when given before and after surgery

Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) reduced the risk of event-free survival events by 60% and reduced the risk of death by 50% when given before and after surgery (radical cystectomy) versus surgery alone, the current standard of care, in patients with muscle-invasive bladder cancer who are not eligible for or declined cisplatin-based chemotherapy, according to phase III KEYNOTE-905/EV-303 trial data. 
Byline
Richard L. Schilsky, MD, FACP, FSCT, FASCO
Professor emeritus, University of Chicago; Former chief medical officer and executive vice president, American Society of Clinical Oncology; Former chair, Cancer and Leukemia Group B
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account